Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia

References

• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. JCO. 2012;30(14):1663–1669.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211–1218.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Ali A, Mohammed MM. Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols. Adv Hematol. 2014;2014:697675.
   PubMedGoogle Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. JCO. 2009;27(6):911–918.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744–2750.
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–471.
   PubMed Web of Science ®Google Scholar
• Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017;31(1):58–64.
   PubMed Web of Science ®Google Scholar
• Burke PW, Aldoss I, Lunning MA, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res. 2018;66:49–56.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Sulz M, Stadlmann S, et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006;74(1):28–32.
   PubMed Web of Science ®Google Scholar
• Reinert RB, Oberle LM, Wek SA, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006;281(42):31222–31233.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23(3):295–299.
   PubMed Web of Science ®Google Scholar
• Villa P, Corada M, Bartosek I. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett. 1986;32(3):235–241.
   PubMed Web of Science ®Google Scholar
• Rausch CR, Paul S, Marx KR, et al. L-carnitine and vitamin B complex for the treatment of pegasparaginase-induced hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. 2018;18(5):e191–e195.
   PubMed Web of Science ®Google Scholar
• Alshiekh-Nasany R, Douer D. L-carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135(4):208–210.
   PubMed Web of Science ®Google Scholar
• Schulte RR, Madiwale MV, Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma. 2018;59(10):2360–2368.
   PubMed Web of Science ®Google Scholar
• Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma. 2014;55(7):1670–1674.
   PubMed Web of Science ®Google Scholar
• Roesmann A, Afify M, Panse J, et al. L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy. 2013;59(3):167–175.
   PubMed Web of Science ®Google Scholar
• Kaya I, Citil M, Sozmen M, et al. Investigation of protective effect of L-carnitine on L-asparaginase-induced acute pancreatic injury in male Balb/c mice. Dig Dis Sci. 2015;60(5):1290–1296.
   PubMed Web of Science ®Google Scholar
• Tung S, Shi Y, Wong K, et al. PPARalpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013;122(6):969–980.
   PubMed Web of Science ®Google Scholar
• Boag JM, Beesley AH, Firth MJ, et al. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia. 2006;20(10):1731–1737.
   PubMed Web of Science ®Google Scholar
• Behan JW, Yun JP, Proektor MP, et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69(19):7867–7874.
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344(6263):251–253.
   PubMed Web of Science ®Google Scholar
• Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel). 2012;12(9):12347–12360.
   PubMed Web of Science ®Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–682.
   PubMed Web of Science ®Google Scholar
• Divakaruni AS, Paradyse A, Ferrick DA, et al. Analysis and interpretation of microplate-based oxygen consumption and pH data. Methods Enzymol. 2014;547:309–354.
   PubMed Web of Science ®Google Scholar
• Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4):299–308.
   PubMed Web of Science ®Google Scholar
• Denton CC, Rawlins YA, Oberley MJ, et al. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891.
   Web of Science ®Google Scholar
• Kon K, Ikejima K, Morinaga M, et al. L-carnitine prevents metabolic steatohepatitis in obese diabetic KK-Ay mice. Hepatol Res. 2017;47(3):E44–E54.
   PubMed Web of Science ®Google Scholar
• Morand R, Bouitbir J, Felser A, et al. Effect of carnitine, acetyl-, and propionylcarnitine supplementation on the body carnitine pool, skeletal muscle composition, and physical performance in mice. Eur J Nutr. 2014;53(6):1313–1325.
   PubMed Web of Science ®Google Scholar
• Cheema UB, Most E, Eder K, et al. Effect of lifelong carnitine supplementation on plasma and tissue carnitine status, hepatic lipid metabolism and stress signalling pathways and skeletal muscle transcriptome in mice at advanced age. Br J Nutr. 2019;121:1–28.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang N, Gao J, et al. The effect of different l-carnitine administration routes on the development of atherosclerosis in ApoE knockout mice. Mol Nutr Food Res. 2018;62 (5):1700299.
   Web of Science ®Google Scholar
• Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96(5):1709–1715.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380.
   PubMed Web of Science ®Google Scholar
• Rausch CR, Marini BL, Benitez LL, et al. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (dagger). Leuk Lymphoma. 2018;59 (3):617–624.
   PubMed Web of Science ®Google Scholar
• Ricciardi MR, Mirabilii S, Allegretti M, et al. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood. 2015;126(16):1925–1929.
   PubMed Web of Science ®Google Scholar
• Gugiatti E, Tenca C, Ravera S, et al. A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. Haematologica. 2018;103(11):e531–e536.
   PubMed Web of Science ®Google Scholar
• Hermanova I, Arruabarrena-Aristorena A, Valis K, et al. Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia. 2016;30(1):209–218.
   PubMed Web of Science ®Google Scholar
• Liu J, Hong J, Ahn K-S, et al. L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model. Leuk Lymphoma. 2019;60(8):2088–2090.
   PubMed Web of Science ®Google Scholar
• Horvath TD, Chan WK, Pontikos MA, et al. Assessment of l-asparaginase pharmacodynamics in mouse models of cancer. Metabolites. 2019;9(1):10.
   Web of Science ®Google Scholar
• Shiromizu S, Kusunose N, Matsunaga N, et al. Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice. J Pharmacol Sci. 2018;136(4):228–233.
   PubMed Web of Science ®Google Scholar